Manuscripts and Publications

Filters: Keyword is Adult and Author is Wilson, Craig M  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
A
Hosek SG, Siberry G, Bell M, Lally M, Kapogiannis B, Green K, M Fernández I, Rutledge B, Martinez J, Garofalo R et al..  2013.  The acceptability and feasibility of an HIV preexposure prophylaxis (PrEP) trial with young men who have sex with men.. J Acquir Immune Defic Syndr. 62(4):447-56.
Havens PL, Kiser JJ, Stephensen CB, Hazra R, Flynn PM, Wilson CM, Rutledge B, Bethel J, Pan CG, Woodhouse LR et al..  2013.  Association of higher plasma vitamin D binding protein and lower free calcitriol levels with tenofovir disoproxil fumarate use and plasma and intracellular tenofovir pharmacokinetics: cause of a functional vitamin D deficiency? Antimicrob Agents Chemother. 57(11):5619-28.
C
Sill AM, Kreisel K, Deeds BGriffin, Wilson CM, Constantine NT, Peralta L.  2007.  Calibration and validation of an oral fluid-based sensitive/less-sensitive assay to distinguish recent from established HIV-1 infections.. J Clin Lab Anal. 21(1):40-5.
Havens PL, Perumean-Chaney SE, Patki A, Cofield SS, Wilson CM, Liu N, Anderson PL, Landovitz RJ, Kapogiannis BG, Hosek SG et al..  2020.  Changes in Bone Mass After Discontinuation of Preexposure Prophylaxis With Tenofovir Disoproxil Fumarate/Emtricitabine in Young Men Who Have Sex With Men: Extension Phase Results of Adolescent Trials Network Protocols 110 and 113.. Clin Infect Dis. 70(4):687-691.
E
Castillo-Mancilla J, Seifert S, Campbell K, Coleman S, McAllister K, Zheng J-H, Gardner EM, Liu A, Glidden DV, Grant R et al..  2016.  Emtricitabine-Triphosphate in Dried Blood Spots as a Marker of Recent Dosing.. Antimicrob Agents Chemother. 60(11):6692-6697.
H
Turnbull EL, A Lopes R, Jones NA, Cornforth D, Newton P, Aldam D, Pellegrino P, Turner J, Williams I, Wilson CM et al..  2006.  HIV-1 epitope-specific CD8+ T cell responses strongly associated with delayed disease progression cross-recognize epitope variants efficiently.. J Immunol. 176(10):6130-46.
I
J Fortenberry D, Koenig LJ, Kapogiannis BG, Jeffries CL, Ellen JM, Wilson CM.  2017.  Implementation of an Integrated Approach to the National HIV/AIDS Strategy for Improving Human Immunodeficiency Virus Care for Youths.. JAMA Pediatr. 171(7):687-693.
L
Mulligan K, D Harris R, Emmanuel P, Fielding RA, Worrell C, Kapogiannis BG, Monte D, Sleasman J, Wilson CM, Aldrovandi GM.  2012.  Low bone mass in behaviorally HIV-infected young men on antiretroviral therapy: Adolescent Trials Network Study 021B.. Clin Infect Dis. 55(3):461-8.
P
Kiser JJ, Fletcher CV, Flynn PM, Cunningham CK, Wilson CM, Kapogiannis BG, Major-Wilson H, Viani RM, Liu NX, Muenz LR et al..  2008.  Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection.. Antimicrob Agents Chemother. 52(2):631-7.
Kahn JA, Belzer M, Chi X, Lee J, Gaur AH, Mayer K, Martinez J, Futterman DC, Stier EA, Paul ME et al..  2019.  Pre-vaccination prevalence of anogenital and oral human papillomavirus in young HIV-infected men who have sex with men.. Papillomavirus Res. 7:52-61.
Viani RM, Peralta L, Aldrovandi G, Kapogiannis BG, Mitchell R, Spector SA, Lie YS, Weidler JM, Bates MP, Liu N et al..  2006.  Prevalence of primary HIV-1 drug resistance among recently infected adolescents: a multicenter adolescent medicine trials network for HIV/AIDS interventions study.. J Infect Dis. 194(11):1505-9.
R
Kahana SY, Fernandez MIsabel, Wilson PA, Bauermeister JA, Lee S, Wilson CM, Hightow-Weidman LB.  2015.  Rates and correlates of antiretroviral therapy use and virologic suppression among perinatally and behaviorally HIV-infected youth linked to care in the United States.. J Acquir Immune Defic Syndr. 68(2):169-77.
S
Wilson PA, Kahana SY, Fernandez MIsabel, Harper GW, Mayer K, Wilson CM, Hightow-Weidman LB.  2016.  Sexual Risk Behavior Among Virologically Detectable Human Immunodeficiency Virus-Infected Young Men Who Have Sex With Men.. JAMA Pediatr. 170(2):125-31.
Rudy BJ, Sleasman J, Kapogiannis B, Wilson CM, Bethel J, Serchuck L, Ahmad S, Cunningham CK.  2009.  Short-cycle therapy in adolescents after continuous therapy with established viral suppression: the impact on viral load suppression.. AIDS Res Hum Retroviruses. 25(6):555-61.
V
Stephensen CB, Marquis GS, Kruzich LA, Douglas SD, Aldrovandi GM, Wilson CM.  2006.  Vitamin D status in adolescents and young adults with HIV infection.. Am J Clin Nutr. 83(5):1135-41.
Havens PL, Hazra R, Stephensen CB, Kiser JJ, Flynn PM, Wilson CM, Rutledge B, Bethel J, Pan CG, Woodhouse LR et al..  2014.  Vitamin D3 supplementation increases fibroblast growth factor-23 in HIV-infected youths treated with tenofovir disoproxil fumarate.. Antivir Ther. 19(6):613-8.